Last Update 17 Mar 26

BFLY: Embedded Platform And Cloud Authorizations Will Support Future Software Like Upside

Narrative Update

Analysts have lifted their price targets on Butterfly Network by up to $1.50 to $6, citing recent Q4 results and growing interest in Butterfly Embedded as an additional revenue stream alongside the core POCUS business.

Analyst Commentary

Bullish analysts are framing the recent price target moves as a reaction to Q4 results and a growing focus on Butterfly Embedded as a separate, software-like revenue driver alongside the core point of care ultrasound, or POCUS, business.

Bullish Takeaways

Bullish analysts view the move in targets up to US$6 as reflecting a shift in the story toward a higher value mix of technology and software revenue, not just hardware.
The commentary that Butterfly Embedded should become a bigger part of the story suggests expectations for a broader customer base and potentially more recurring or licensing style revenue tied to software integrations.
Positive references to Q4 results support the view that execution against current plans is on track, which can help analysts gain confidence in valuation assumptions at higher target prices.
Positioning the company as "more tech than med tech" signals that some analysts may be applying tech style multiples in their frameworks, which typically place more weight on software, data and platform potential.

Bearish Takeaways

While targets have been lifted, the focus on Butterfly Embedded as "the bigger part of the story" also highlights execution risk, since the business still needs to prove the scale and durability of this newer revenue stream.
Framing the company as more tech than med tech could set a higher bar for growth and consistency, which may be challenging if adoption of embedded solutions takes longer than analysts expect.
The emphasis on Q4 results in recent commentary signals that expectations are now tied closely to continued delivery on similar performance, so any operational setbacks could pressure valuation assumptions.
Shifts in how the business is categorized, from med tech toward tech, may lead to valuation frameworks that are less forgiving if the company does not meet the execution and growth profiles investors usually associate with software oriented names.

What's in the News

Issued revenue guidance for fiscal 2026, with expected revenue of US$117m to US$121m, described as approximately 20% to 24% growth. This provides a clearer sense of the company’s medium term targets (Key Developments).
Provided revenue guidance for Q4 2025, indicating expected revenue growth of at least 17% year over year. This sets a reference point for how management is thinking about near term performance (Key Developments).
Announced that Butterfly iQ+/iQ3 and Compass AI ultrasound solution achieved GovRAMP and TX-RAMP authorizations, allowing the company to sell cloud services to U.S. state and local government agencies, including Texas, under standardized security and compliance frameworks (Key Developments).
Outlined plans to release a Beam Steering API in the first half of 2026 for third party AI and technology development within Butterfly Garden and Ultrasound-on-Chip programs, with planned support across multiple imaging presets, subject to ongoing development, regulation, and partner agreements (Key Developments).

Valuation Changes

Fair Value: $5.56 is unchanged, with no adjustment to the central valuation estimate in this update.
Discount Rate: 7.71% to 7.72%, risen slightly, implying a marginally higher required return in the model.
Revenue Growth: 16.87% to 16.20%, reduced slightly, pointing to a more cautious view on future dollar revenue expansion.
Net Profit Margin: 13.40% to 13.36%, trimmed slightly, indicating only a minor change to long term profitability assumptions.
Future P/E: 92.25x to 94.12x, risen slightly, suggesting a modestly higher earnings multiple applied in the updated assumptions.

24 views

Key Takeaways

Expanding enterprise deals, clinical AI apps, and HomeCare pilots position Butterfly for growth in recurring digital revenue aligned with decentralized, accessible healthcare trends.
Product and software innovations, cost reductions, and successful commercialization efforts support higher adoption, improved gross margins, and pave the way to scalable profitability.
Sluggish domestic growth, global revenue volatility, high R&D expenses, and executive instability threaten profitability and undermine financial performance and customer retention.

Catalysts

About Butterfly Network

Develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Butterfly's pipeline of large enterprise and medical school deals, bolstered by recent success in landing a top global health system for full deployment, points to accelerating penetration of handheld ultrasound solutions as healthcare systems shift toward more accessible, cost-effective, point-of-care diagnostics-supporting forward-looking revenue growth as funding clarity returns.
The launch of next-generation Compass AI software, with automated documentation and workflow enhancements, is expected to drive increased enterprise adoption and higher software subscription revenues, improving gross margin mix and boosting earnings via a greater share of recurring, high-margin digital revenue.
Commercialization of Butterfly Garden's clinical AI apps (e.g., HeartFocus, iCardio) expands the addressable market by enabling health professionals without prior ultrasound training to perform advanced diagnostics, catalyzing device sales, software adoption, and new recurring revenue streams-directly aligned with rising global demand for affordable, scalable healthcare solutions.
Progress on the HomeCare pilot, targeting large populations of heart failure patients with portable, AI-assisted ultrasound and remote specialist diagnosis, validates Butterfly's unique position to capitalize on the healthcare trend toward preventive, decentralized care, with the potential to generate significant new revenue and improve net margins as contracts expand state
and nation-wide.
Ongoing advances in semiconductor manufacturing, new product launches (e.g., iQ Station, upcoming fourth-generation P5 technology), and cost containment efforts are driving product miniaturization and lower production costs, supporting higher gross margins and a credible path to sustainable profitability at scale as portable imaging adoption accelerates globally.

Butterfly Network Earnings and Revenue Growth

Butterfly Network Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Butterfly Network's revenue will grow by 15.8% annually over the next 3 years.
Analysts are not forecasting that Butterfly Network will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Butterfly Network's profit margin will increase from -71.8% to the average US Medical Equipment industry of 12.5% in 3 years.
If Butterfly Network's profit margin were to converge on the industry average, you could expect earnings to reach $17.0 million (and earnings per share of $0.06) by about September 2028, up from $-62.8 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 71.6x on those 2028 earnings, up from -6.0x today. This future PE is greater than the current PE for the US Medical Equipment industry at 28.6x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.58%, as per the Simply Wall St company report.

Butterfly Network Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent delays in closing large enterprise and medical school deals, along with extended sales cycles due to healthcare funding uncertainty and changes in government programs, may lead to lower-than-expected revenue growth as customers defer capital spending.
Flat domestic revenue and lower renewal rates for individual software subscriptions suggest Butterfly may struggle with customer stickiness and retention in its core market, which could pressure both recurring revenue and net margins.
Reliance on growth in international markets, coupled with disruptions and pauses in global health projects due to cuts in NGO/public funding, introduces volatility and unpredictable revenue streams, potentially impacting overall earnings stability.
Ongoing high R&D and investment needs to advance AI and semiconductor technology (including P5 development and new software platforms) could result in continued operating losses and delay breakeven, negatively affecting profitability and earnings per share.
Transition in executive leadership, including the departure of the CFO and dependence on an interim replacement during a critical execution period, could disrupt strategic focus and operational continuity, potentially impacting financial performance and investor confidence.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $3.167 for Butterfly Network based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $4.0, and the most bearish reporting a price target of just $2.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $135.9 million, earnings will come to $17.0 million, and it would be trading on a PE ratio of 71.6x, assuming you use a discount rate of 7.6%.
Given the current share price of $1.5, the analyst price target of $3.17 is 52.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Butterfly Network?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

AI And Portable Imaging Will Advance Global Healthcare Diagnostics